Get informed when a big investor buys or sells
+ Follow56.71%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Sunmax Biotechnology , Ltd. posts a ROE of 56.71%. That is above the Healthcare sector average of 13.1%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 13.1% is typical. Sunmax Biotechnology , Ltd.'s 56.71% is higher that level. That is roughly 332.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Sunmax Biotechnology , Ltd.'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 56.71%; use YoY and peer views to separate noise from signal.
Context for 4728.TWO's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.1%), and (3) consistency with growth and profitability. This page covers the first two; Sunmax Biotechnology , Ltd.'s other metric pages and overview cover the third.
Judging Sunmax Biotechnology , Ltd. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 56.71% here, then scan peer and history charts to see if the gap is persistent.